The endogenous hypothalamic hormone that directly stimulates pituitary growth hormone release — the natural GH trigger.
Growth Hormone Releasing Hormone (GHRH) is a 44-amino acid peptide produced by the arcuate nucleus of the hypothalamus. It is the primary endogenous stimulator of growth hormone (GH) synthesis and secretion from pituitary somatotroph cells. GHRH acts on GHRH receptors (GHRH-R) on the pituitary, activating cAMP/PKA pathways that promote GH gene transcription, synthesis, and pulsatile release.
All synthetic GHRH analogs — sermorelin (GHRH 1-29), CJC-1295, tesamorelin — are derived from the natural GHRH sequence. The full-length GHRH (1-44) is the parent molecule from which these analogs were developed. Understanding native GHRH is essential for understanding the entire GH secretagogue peptide class.
GHRH works synergistically with GHRPs (like ipamorelin) and is inhibited by somatostatin (the counter-regulatory 'brake' on GH release). The pulsatile pattern of GHRH release creates the natural GH pulses that occur primarily during deep sleep.
GHRH was isolated and characterized in the early 1980s, leading to Nobel Prize-related work in neuroendocrinology. Clinical studies established GHRH's role in diagnosing GH deficiency (GHRH stimulation test) and treating GH-deficient states. The development of analogs with better pharmacokinetics largely superseded native GHRH for therapeutic use.
Research on aging shows GHRH secretion declines with age, contributing to the somatopause — the age-related decline in GH and IGF-1 levels. GHRH analog supplementation in elderly populations has shown improvements in body composition, sleep quality, and immune function.
📚 Key Reference: PMID: 6134108 (GHRH isolation)
Native GHRH has a short half-life (~7 minutes), limiting its therapeutic utility vs. analogs. Safety profile is well-characterized from decades of diagnostic and research use. Side effects relate to GH elevation: fluid retention, joint pain, glucose intolerance at excessive doses. Monitor IGF-1. Consult your provider.
GHRH itself is not FDA-approved as a therapeutic. GHRH analogs (sermorelin, tesamorelin) have/had FDA approval. Available through compounding.